Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Children's Oncology Group
With
OBJECTIVES: Primary * Determine whether very low-dose cytarabine can improve event-free survival (EFS) rates in infants with high-risk transient myeloproliferative disorder (TMD), using high-risk TMD patients from clinical trial COG-A2971 for historic comparison, and in infants with intermediate-risk TMD, using intermediate-risk TMD patients from clinical trial COG-A2971 for historic comparison. * Maintain the current high overall EFS rate in low-risk TMD patients. Secondary * Assess the toxicity of this regimen in these patients. OUTLINE: This is a nonrandomized, multicenter, crossover study. Patients are stratified according to disease risk (high or intermediate vs low). * Group I (patients with high- or intermediate-risk transient myeloproliferative disorder \[TMD\]): Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation. * Group II (patients with low-risk TMD): Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I. After completion of study treatment, patients are followed periodically for 10 years. PROJECTED ACCRUAL: A total of 180 patients will be accrued for this study.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
